Global AI Drug Discovery Market Confirmed at $1.13B (2025); Eli Lilly Opens 'LillyPod' AI Supercomputer with 1,016 NVIDIA Blackwell GPUs

A comprehensive global market analysis published by Research and Markets via GlobeNewswire on May 8, 2026 confirmed that the AI in drug discovery market reached $1.13 billion in 2025 and is projected to grow to $2.29 billion by 2031, driven by adoption across major pharmaceutical companies. The report cites Pfizer's use of AI to screen millions of compounds and identify drug candidates in 30 days as a benchmark case for AI-accelerated discovery. The market analysis arrives alongside major industry infrastructure investments: Eli Lilly opened 'LillyPod,' a dedicated pharmaceutical AI supercomputer built on 1,016 NVIDIA Blackwell Ultra GPUs, designed to run AI-powered drug screening and compound optimization across Lilly's diabetes, oncology, and immunology pipelines. Separately, the $2.75 billion discovery and development agreement between Eli Lilly and Insilico Medicine — signed March 29, 2026 and the largest single AI drug discovery partnership to date — confirms that AI has moved from a supplementary research tool to a primary driver of pharmaceutical company pipeline strategy. For global health, the scale of AI screening investment raises the prospect of accelerated compound discovery in diseases where molecular targets are known but candidate compounds remain elusive — including drug-resistant tuberculosis, malaria, and neglected tropical diseases. The transition of AI drug discovery from venture-funded startups to embedded Big Pharma infrastructure is the defining trend of 2025-2026 in this space.